Clinical Study
Sucrose-Formulated Recombinant Factor VIII Dosing Flexibility in Prophylaxis Regimens: Experience from Postmarketing Surveillance Studies
Table 2
Annualized bleeding rates by dosing group.
| Annualized bleeding rates | Prophylaxis 1-2x/wk () | Prophylaxis ≥3x/wk () |
| All bleeds | | | Mean ± SD | 4.1 ± 6.4 | 7.0 ± 10.7 | Median (Q1; Q3) | 2.0 (0; 4.0) | 3.9 (1.5; 9.3) | Joint bleeds | | | Mean ± SD | 2.8 ± 5.2 | 4.5 ± 7.0 | Median (Q1; Q3) | 0.9 (0; 2.6) | 2.4 (0.6; 5.5) | Spontaneous bleeds | | | Mean ± SD | 2.4 ± 5.0 | 3.1 ± 6.2 | Median (Q1; Q3) | 0 (0; 1.9) | 0.9 (0; 3.7) | Trauma-related bleeds | | | Mean ± SD | 1.6 ± 3.7 | 3.4 ± 5.4 | Median (Q1; Q3) | 0.6 (0; 2.0) | 1.5 (0.5; 4.6) |
|
|
Q1 = quartile 1; Q3 = quartile 3.
|